In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine-Reference-Cited by-同舟云学术

In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine

Published:2005-09 Issue:9 Volume:49 Page:3930-3932
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hammond Jennifer L.¹,Parikh Urvi M.¹,Koontz Dianna L.¹,Schlueter-Wirtz Susan²,Chu Chung K.³,Bazmi Hengameh Z.¹,Schinazi Raymond F.²,Mellors John W.¹

Affiliation:

1. Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261

2. Department of Pediatrics, Emory University School of Medicine, and the Georgia VA Research Center on AIDS and HIV Infection, Veterans Affair Medical Center, Decatur, Georgia 30033

3. College of Pharmacy, The University of Georgia, Athens, Georgia 30602

Abstract

ABSTRACT Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d - and l -enantiomers of β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l -d4FC and I63L, K65R, K70N, K70E, or R172K for d -d4FC. Phenotypic analysis of site-directed mutants defined the role of these mutations in reducing susceptibility to l - or d -d4FC.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.9.3930-3932.2005

Reference15 articles.

1. In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β- d -Dioxolane-Guanosine and Suppress Resistance to 3′-Azido-3′-Deoxythymidine

2. Geleziunas, R., K. Gallagher, H. Zhang, L. Bacheler, S. Garber, J.-T. Wu, G. Shi, M. J. Otto, R. F. Schinazi, and S. Erickson-Viitanen. 2003. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor β-d-2,3-dideoxy-2,3-didehydro-5-fluorocytidine (Reverset™). Antivir. Chem. Chemother.14:49-59.

3. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science282:1669-1674.

4. Kinjerski, T. L., and R. W. Buckheit, Jr. 1997. The role of genotypic heterogeneity in wild type virus populations on the selection of non-nucleoside reverse transcriptase inhibitor resistant viruses. Antivir. Res.33:109-115.

5. Kleim, J. P., I. Winkler, M. Rosner, R. Kirsch, H. Rubsamen-Waigmann, A. Paessens, and G. Riess. 1997. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology231:112-118.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 Resistance to Reverse Transcriptase Inhibitors;Handbook of Antimicrobial Resistance;2017

2. HIV-1 Resistance to Reverse Transcriptase Inhibitors;Handbook of Antimicrobial Resistance;2014

3. HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors;Journal of Biological Chemistry;2012-08

4. HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions;Molecular Biology International;2012-06-20

5. Selection and Characterization of HIV-1 with a Novel S68 Deletion in Reverse Transcriptase;Antimicrobial Agents and Chemotherapy;2011-02-28